Biomarker Development in LGMD 2i
Learn more about:
Related Clinical Trial
Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)
Trial Readiness and Endpoint Assessment in LGMD R1
A Phase 1/2 Dose-escalation Study to Evaluate the Safety of LION-101 in Adult Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)
3 Year Follow up on ANO5 Patients
A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)
MRI and Muscle Involvement in Patients With Mutations in GMPPB
Fast Troponin as a Biomarker to Assess Exercise-induced Muscle Damage in Muscle Diseases
Limb-Girdle Muscular Dystrophy Type 2I in Norway
Muscle MRI in Becker Muscular Dystrophy and in Limb-girdle Muscular Dystrophy Type 2I
Natural History of Limb Girdle Muscular Dystrophy Type 2A and Type 2E
MRI on Persons With Mutations in POMT2 Gene (LGMD2N)
Biomarker Development in LGMD 2i